Myelodysplastic Syndrome (MDS) | Clinical Medicine

Main ideas / lessons from the video

What MDS is

• Myelodysplastic syndrome (MDS) is a disorder of the bone marrow.
• Core concept: MDS involves mutations in hematopoietic (blood-forming) stem cells, causing them to become dysplastic (abnormal).
• Dysplastic stem cells can:
  • Suppress normal stem cell division/differentiation (via cytokines)
  • Trigger apoptosis (leading to fewer functional blood-forming cells)
  • Take over and produce ineffective blood cells

Why patients become sick (cell line effects)

• Decreased production across multiple cell lines → pancytopenia
  • Loss of ability to make red cells, white cells, and platelets
  • Presence is described as an ominous/bad sign
• Macrocytic anemia (very common presentation)
  • Dysplastic stem cells make large, abnormal red blood cells, but ineffectively
  • Leads to reduced effective erythropoiesis, causing:
    • fatigue
    • pallor
    • possible dyspnea if severe
  • Reminder: don’t assume macrocytic anemia is always due to B12/folate deficiency; keep MDS on the differential
• Thrombocytopenia / bleeding risk
  • Ineffective platelet production and/or reduced platelets
  • Can cause petechiae, bruising, gum bleeding, epistaxis, etc.
• Neutropenia / infection risk
  • Ineffective leukopoiesis → low neutrophils
  • Results in recurrent infections and fevers

Progression risk: MDS → AML

• Dysplastic cells can further mutate and transition into myoblasts.
• When myoblasts exceed ~20% in the marrow, the risk increases for acute myeloid leukemia (AML).
• The video highlights:
  • ~30% of MDS patients can convert to AML over time
  • Many patients die from MDS-related complications (anemia, bleeding, infection) before transformation
• AML can cause oncologic emergencies:
  • Tumor lysis syndrome
    • hyperphosphatemia → hypocalcemia → tetany
    • hyperuricemia → acute kidney injury
    • hyperkalemia → EKG changes/arrhythmias
  • Leukostasis
    • clogging small vessels → stroke-like events, pulmonary symptoms, tissue ischemia
  • DIC (especially mentioned as more common in APL variant)
    • tissue factor–driven clotting with consumption of clotting factors/platelets → both clotting and bleeding

---

Diagnostic approach / “methodology” described (step-by-step)

1) Start with what the CBC/peripheral smear shows

• Obtain CBC + peripheral blood smear
• Use them to identify which cell lines are affected:
  • macrocytic anemia pattern
  • platelet reduction
  • white cell reduction (especially neutrophils)
  • abnormal neutrophil morphology

2) If macrocytic anemia is present (high MCV)

• Check for megaloblastic causes first
  • Look for hypersegmented neutrophils on smear
    • If present → suspect a DNA synthesis/maturation problem
    • Treat as megaloblastic anemia
  • Workup sequence:
    • Check B12
      • if deficient → B12 deficiency pathway
    • Check folate
      • if low → folate deficiency pathway
    • If B12/folate are borderline/equivocal
      • order MMA (methylmalonic acid) and homocysteine to distinguish functional deficiency
• If no hypersegmented neutrophils
  • Consider non-megaloblastic macrocytosis differential, including:
    • medications
    • liver disease
    • thyroid disease
    • alcoholism
    • MDS
  • Look for suggestive smear findings:
    • Pseudo–Pelger-Huët neutrophils (weird-looking neutrophils)
      • presence raises strong concern for MDS
      • may prompt bone marrow biopsy

3) When smear suggests MDS → confirm with bone marrow biopsy

Bone marrow biopsy is needed to assess:

• Marrow cellularity (can be hypercellular)
• Percent myeloblasts (myoblasts)
• Evidence of dysplasia in red cells, white cells, and platelets

Key threshold stated:

• < 20% myeloblasts with dysplasia → suggests MDS
• ≥ 20% myeloblasts with high blasts/hypercellular marrow → suggests AML

4) After confirming MDS → get cytogenetics

• Perform cytogenetic testing, specifically to look for:
  • del(5q) / “5Q deletion”
• Purpose:
  • prognosis and treatment selection
• The video characterizes treatment implications:
  • With 5Q deletion
    • lower-risk MDS
    • targeted therapy: lenalidomide
  • Without 5Q deletion
    • higher-risk MDS
    • different therapy: azacitidine
    • transplant considerations may come up

---

Prognosis framework presented

• Risk depends on multiple factors:
  • Cytogenetics (especially 5Q deletion)
  • how many cell lines are affected
  • severity/extent of cytopenias
    • anemia alone → better prognosis
    • pancytopenia → worse prognosis
  • Blast burden
    • more marrow blasts → poorer prognosis
    • <20% blasts supports lower-risk in the explanation

---

Treatment approach described (with detailed conditional instructions)

Overall goals

• Support cytopenia complications (anemia/bleeding/infection)
• Disease-modifying therapy based on risk and cytogenetics
• Curative intent: hematopoietic stem cell transplant (only for eligible patients)

---

A) Treat associated cytopenias (supportive care)

1) Anemia

• Transfuse packed red blood cells when:
  • Hgb < 7, or
  • Hgb < 8 with symptoms or hypotension, or pre-existing coronary artery disease
• EPO-directed therapy
  • If EPO levels are low, consider erythropoietin (EPO agents)
  • If EPO is normal/high, rely on transfusion

2) Thrombocytopenia / bleeding

• Platelet transfusion thresholds (as stated):
  • < 10,000 if asymptomatic
  • < 50,000 if bleeding or preparing for surgery
  • < 100,000 if bleeding in the brain or preparing for neurosurgery
• Otherwise, avoid transfusing unless needed

3) Neutropenia / leukopenia

• G-CSF may be used to:
  • stimulate neutrophil production
  • reduce infections/fevers
• The video notes this is less commonly used than transfusion support

---

B) Disease-modifying / MDS-directed therapy (based on risk)

1) Lower-risk MDS

• If 5Q deletion is present
  • If transfusion dependence develops → use lenalidomide
  • Dual actions described:
    • promotes apoptosis of dysplastic cells
    • causes cell-cycle arrest by inhibiting specific enzymes
• If no 5Q deletion but the case fits “low-risk” framing:
  • the strategy discussed is mostly supportive, and/or EPO if EPO is low, plus transfusions

2) Higher-risk MDS

• Check transplant eligibility
  • If eligible, stem cell transplant is described as the “theoretical cure”
• If not eligible for transplant and no 5Q deletion
  • use azacitidine (described as a hypomethylating agent)
  • mechanism described as affecting methylation/cell-cycle regulation to reduce the proliferative response

---

C) Escalation logic the video uses (how to choose what to do)

• Low-risk
  • Confirm <20% blasts, limited cytopenias, and/or 5Q deletion
  • Begin with supportive care (transfusions and/or EPO if EPO is low)
  • If 5Q deletion and patient becomes transfusion-dependent → lenalidomide
• High-risk
  • If many blasts, multiple cell lines affected, and no 5Q deletion → high-risk
  • Attempt stem cell transplant if eligible
  • If not eligible → azacitidine

---

What a patient with MDS “looks like” (symptom patterns)

• Often incidentally found on CBC/peripheral smear, or presents with:
  • anemia symptoms: fatigue, pallor, possible dyspnea
  • bleeding symptoms from thrombocytopenia: bruising, petechiae, gum bleeding, epistaxis
  • infection symptoms from neutropenia: recurrent fevers/infections

---

Speakers / sources featured

• No specific individual name is given in the subtitles.
• One main speaker/lecturer addresses the audience in an educational monologue style.
• No external sources/citations are mentioned in the subtitles.